Pentasa is an immunosuppressive drug.

the verdict

REFUTED

the evidence says no

Recorded sources

0 sources for · 2 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Pentasa contains mesalazine (5-aminosalicylic acid), which acts locally as an anti-inflammatory agent in the gastrointestinal tract rather than as an immunosuppressive drug.

The analysis

The claim states that Pentasa is an immunosuppressive drug. Pentasa's active ingredient is mesalazine (mesalamine or 5-ASA), which is classified as an aminosalicylate and conventional anti-inflammatory medication used in inflammatory bowel disease, whereas true immunomodulators/immunosuppressants in this context typically refer to agents like azathioprine, mercaptopurine, or methotrexate. Therefore, the claim is incorrect and refuted by the pharmacological classification shown in the literature.

Evidence against · 2

Mesalazine in inflammatory bowel disease: a trendy topic once again?

Recorded source metadata

M. Iacucci, Shanika de Silva, Sabra B. Ghosh. Mesalazine in inflammatory bowel disease: a trendy topic once again?. 2010. https://doi.org/10.1155/2010/586092

Paper [0] identifies Pentasa's active ingredient as mesalazine (5-ASA), a conventional anti-inflammatory and chemopreventive agent distinct from true immunosuppressants.

Source citation format

See more details

More against · 1

The 2023 Impact of Inflammatory Bowel Disease in Canada: Treatment Landscape.

Recorded source metadata

Murthy SK, Weizman AV, Kuenzig ME, Windsor JW, Kaplan GG, Benchimol EI, Bernstein CN, Bitton A, Coward S, Jones JL, Lee K, Peña-Sánchez JN, Rohatinsky N, Ghandeharian S, Sabrie N, Gupta S, Brar G, Khan R, Im JHB, Davis T, Weinstein J, St-Pierre J, Chis R, Meka S, Cheah E, Goddard Q, Gorospe J, Kerr J, Beaudion KD, Patel A, Russo S, Blyth J, Blyth S, Charron-Bishop D, Targownik LE. The 2023 Impact of Inflammatory Bowel Disease in Canada: Treatment Landscape.. 2023. https://doi.org/10.1093/jcag/gwad015

Paper [3] contrasts traditional anti-metabolite immunomodulators and targeted biologics with conventional treatments like 5-ASAs for inflammatory bowel disease.

Source citation format

The paper trail · every fact has a biography

first checked02 Aug 2026

judged → REFUTED · 2202 Aug 2026

More receipts

Is it true that Phonological evolution involves regular processes of phoneme elision, vowel nasalization, and tonogenesis?Is it true that Hemangiomas are treatable with medication?Is it true that Research identifies forms of intelligence that diverge from standard IQ measures?

Random receipt →The Trust Wiki →

Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.

Check your own claim

Challenge the receipt

I have a source that contradicts this verdict I have a source that supports it No source: request a receipt review Requests are recorded for review. This does not start an automatic check or guarantee a response time.

trust me, bro: win the argument, pass the class, survive peer review.

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work · Dispute this receipt